Life Biosciences's banner

Life Biosciences

@lifebiosciences • 20,641 subscribers

Aging can be redefined. We're leading the way.

Shorts

Proud to be featured in TIME TIME100 Companies: New Frontiers, recognizing our work to reverse age-related diseases by targeting the biology of aging. We’re honored by this recognition & remain committed to advancing transformative therapies. Read more:

Proud to be featured in TIME TIME100 Companies: New Frontiers, recognizing our work to reverse age-related diseases by targeting the biology of aging. We’re honored by this recognition & remain committed to advancing transformative therapies. Read more:

13,436 просмотров

Welcome David Guyer, MD, to our Board of Directors! With over 30 years of drug development experience, he brings invaluable expertise as we continue advancing our Partial Epigenetic Reprogramming Platform toward the clinic in 2026. Read more:

Welcome David Guyer, MD, to our Board of Directors! With over 30 years of drug development experience, he brings invaluable expertise as we continue advancing our Partial Epigenetic Reprogramming Platform toward the clinic in 2026. Read more:

40,512 просмотров

We’ve closed a fully-subscribed $80 million financing to support our ongoing clinical trial in optic neuropathies and advancement of our Partial Epigenetic Reprogramming platform across multiple indications. Read more:

We’ve closed a fully-subscribed $80 million financing to support our ongoing clinical trial in optic neuropathies and advancement of our Partial Epigenetic Reprogramming platform across multiple indications. Read more:

14,008 просмотров

Q1 kicked off with strong momentum as our leadership team engaged across key industry forums, sharing perspectives on our Partial Epigenetic Reprogramming platform aimed at reversing age-related disease. Stay up to date on our progress:

Q1 kicked off with strong momentum as our leadership team engaged across key industry forums, sharing perspectives on our Partial Epigenetic Reprogramming platform aimed at reversing age-related disease. Stay up to date on our progress:

12,547 просмотров

We’re pleased to announce we’ve received FDA IND clearance for our cellular rejuvenation therapy using partial reprogramming for optic neuropathies, including glaucoma and NAION. Read more in our press release:

We’re pleased to announce we’ve received FDA IND clearance for our cellular rejuvenation therapy using partial reprogramming for optic neuropathies, including glaucoma and NAION. Read more in our press release:

14,586 просмотров

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

This quarter, our leadership team shared progress and insights across longevity science and innovation. We’re energized to build on these advances and continue moving toward the clinic in 2026. Stay up to date with our progress:

This quarter, our leadership team shared progress and insights across longevity science and innovation. We’re energized to build on these advances and continue moving toward the clinic in 2026. Stay up to date with our progress:

Life Biosciences

46,125 просмотров • 6 месяцев назад

Больше нет контента для загрузки